文献速递前列腺增生与排尿功能障碍

比较直接口服抗凝药在前列腺经尿道切除术中的围手术期出血风险

Comparison of perioperative bleeding risk between direct oral anticoagulants in transurethral resection of prostate.
PubMed 文献 · BJU Int · 2024-08-29

单中心回顾性队列分析2019年4月至2023年12月因良性前列腺增生行经尿道前列腺切除术的患者,评估抗凝与未抗凝患者围手术期出血及血栓栓塞风险。629例中113例(18%)接受抗凝治疗,抗凝患者急性出血风险为1.6倍、血尿持续超过14天风险为11倍;与阿哌沙班相比,利伐沙班急性出血风险增加2.21倍;抗凝患者围手术期卒中风险显著增加(未抗凝 vs 抗凝:0.4% vs 2.7%,P=0.01)。

要点

  • 抗凝患者经尿道前列腺切除术后急性出血风险为未抗凝者的1.6倍。
  • 抗凝患者血尿持续超过14天的风险为未抗凝者的11倍。
  • 与阿哌沙班相比,利伐沙班急性出血风险增加2.21倍。

核心结论

  • 抗凝患者尽管停用抗凝治疗,围手术期仍更可能发生血尿和卒中;阿哌沙班引起的出血相关并发症似乎少于利伐沙班。

研究设计与样本

  • 单中心回顾性队列分析,纳入2019年4月至2023年12月因良性前列腺增生行经尿道前列腺切除术的患者629例,其中113例(18%)接受抗凝治疗。

主要发现

  • 抗凝患者急性出血风险为未抗凝者的1.6倍,差异有统计学意义。
  • 抗凝患者血尿持续超过14天的风险为未抗凝者的11倍。
  • 与阿哌沙班相比,利伐沙班急性出血风险增加2.21倍,差异有统计学意义。
  • 围手术期卒中风险未抗凝组 vs 抗凝组:0.4% vs 2.7%,P=0.01。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the perioperative morbidity and mortality associated with direct oral anticoagulants (DOACs) and warfarin for patients receiving transurethral resection of prostate (TURP). PATIENTS AND METHODS: This was a single-centre, retrospective cohort analysis of patients who underwent TURP for benign prostate hyperplasia from April 2019 to December 2023. The primary objective was to evaluate the perioperative bleeding and thromboembolic risk between anticoagulated (AC) vs no-AC patients. The secondary objective was to evaluate perioperative bleeding and thromboembolic risk between different formulations of DOACs. Patient demographics, prior treatment, prostate size, baseline bleeding risk, and operative details were collected. Bleeding and thromboembolic-related morbidity were captured within a 3-month postoperative period. Perioperative management of AC therapy was recorded, and all patients had their AC therapy withheld. Cohort characteristic between the AC vs no-AC, and DOAC groups were analysed with two-sided t-test, and chi-square test. Further logistic regression analyses were carried out to identified significant variables between the groups. These significant variables were used for adjustment in inverse probability-weighted treatment effect analysis to evaluate bleeding risk. RESULTS: There were 629 patients in the cohort, and 113 (18%) patients were receiving AC therapy. The AC patients were at 1.6 times statistically significant increased risk of acute bleeding, and 11 times increased risk of prolonged haematuria for >14 days. When compared to apixaban, patients on rivaroxaban conferred a statistically significant increased risk of acute bleeding by 2.21 times. Patients receiving AC therapy had a statistically significant increased risk of stroke in the perioperative setting (no-AC vs AC: 0.4% vs 2.7%, P = 0.01). CONCLUSION: This is the first study to evaluate risk of bleeding for TURP patients receiving DOACs. The AC patients are more likely to experience haematuria and stroke in the perioperative period despite withholding therapy. Apixaban appears to cause less bleeding-related complications than rivaroxaban.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kuo LY, Kuo J, Silverman J, et al. Comparison of perioperative bleeding risk between direct oral anticoagulants in transurethral resection of prostate. BJU Int. 2024. PMID: 39210619. doi:10.1111/bju.16478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。